S2B-1 A Study of Diagnosis and Early Efficacy Prediction Biomarkers for Major Depressive Disorder  

作　　者：袁勇贵 YUAN Yong-gui

机构地区：[1]Department of Psychosomatic Medicine,Zhongda Hospital,Southeast University

出　　处：《神经药理学报》2018年第4期42-43,共2页Acta Neuropharmacologica

摘　　要：Background:Currently,diagnosis of major depressive disorder(MDD)still relies on symptoms.There are some problems for the diagnostic criteria,like low diagnostic consistency and difficulty in differentiation of MDD and bipolar depression(BD)in the early stage.In terms of treatment,there are also many problems,such as low overall efficiency,slow onset effect,and large differences between individuals.At present,there are a lot of researches on MDD biomarkers,most focus on genomics,transcriptomics,proteomics and brain imaging both from domestic and foreign counterparts,but the main research focuses are genetics and imaging.This study is mainly combine genetics and imaging to conduct the discussions of MDD diagnosis and efficacy prediction biomarkers.Methods:Proteomics mainly included patients who met the diagnostic criteria.Blood samples were taken from the participants.Serum was collected after centrifugation for serum protein concentration detection.Receiver operation curve(ROC)analysis was used to test the diagnostic and differential powers of the single serum proteins or combined serum proteins.In the imageology groups,the 3.0T cranial magnetic resonance imaging(MRI)scan was performed on the subjects meeting the inclusion criteria,and the methods based on the deep learning of the resting-state fMRI data was used.The biological marker spectrums from molecular levels(genotyping or measuring genetic products)to clinical levels(depicting cognitive and motivational areas or clinical symptoms)to predict the outcome of the treatment.Results:In the diagnosis of MDD,accord to the results of previous animal experiments and clinical studies,we developed a highly accurate MDD diagnostic platform based on the serum levels of proteins in the P11-tPA-BDNF pathway.The sensitivity of the MDD diagnostic platform was 88.1%,specificity was 92.7%,and accuracy was as high as 90.6%.Based on the above findings,we further studied the diagnosis and differential diagnosis efficacy of serum proteins levels in this pathway for five common ps

关 键 词：major DEPRESSIVE DISORDER DIAGNOSIS efficacy PREDICTION proteomics NEUROIMAGING 

分 类 号：G[文化科学]